Fig. 5. Potential use of cell-based transcriptomic data for drug therapy induced adverse events.

The flowcharts summarize how integration of experimentally gathered transcriptomic data with publicly available pathway and genomic data bases can (A) help predict toxicity of drug candidates, (B) identify potential new drug targets to mitigate cardiotoxicity and (C) enable design of clinical studies to associate genomic variants with cardiotoxicity propensity. All three flow charts are used with permission from Mount Sinai Health System, licensed under CC BY.